GeneDx Quarterly Cash Flow Statement
NASDAQ: WGSHealth CareMedical/Nursing ServicesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
GeneDx free cash flow
In the quarter ended Jun 30, 2026, GeneDx generated -$29.0 million of operating cash flow and spent $10.1 million on capital expenditures. That left free cash flow of -$39.1 million, a free-cash-flow margin of -34.2% of revenue. Free cash flow was down 585.6% from the prior year's $8.1 million.
Summary generated from market data by MetaCap's automated system. Methodology
GeneDx cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -17.74M | -63.32M | -17.67M | -7.63M | 10.81M | -6.53M | 5.44M | -8.31M | -29.17M | -20.24M | -25.77M | -42.29M |
| Net Income growth (YoY) | -264.12% | — | -424.86% | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 3.10M | 2.70M | 2.77M | 2.37M | 2.30M | 2.20M | 2.02M | 2.42M | 1.71M | 1.74M | 2.58M | 5.17M |
| Stock-Based Compensation | 6.34M | 9.00M | 9.78M | 10.59M | 7.81M | 3.98M | 2.85M | 3.64M | 3.11M | -451.00K | -912.00K | 430.00K |
| Change in Working Capital | -11.74M | -14.04M | -9.88M | -13.59M | -4.33M | 235.00K | -12.50M | -9.88M | -2.51M | -3.39M | -9.16M | -12.79M |
| Operating Cash Flow | -28.98M | -32.41M | -3.09M | 15.77M | 10.42M | 10.18M | -3.18M | -4.39M | -4.50M | -16.41M | -29.86M | -41.23M |
| Capital Expenditures | -10.11M | -6.45M | -4.35M | -6.17M | -2.37M | -6.13M | -3.05M | -646.00K | -1.35M | -443.00K | -2.38M | -112.00K |
| Investing Cash Flow | -5.63M | -17.25M | -11.07M | -4.69M | -36.35M | -9.41M | -519.00K | -7.75M | -22.70M | 843.00K | -4.86M | -27.13M |
| Financing Cash Flow | 1.00M | 38.59M | 23.19M | 10.77M | 346.00K | 13.72M | 31.02M | 13.97M | -391.00K | -438.00K | 47.10M | -911.00K |
| Net Change in Cash | -33.61M | -11.07M | 9.03M | 21.85M | -25.58M | 14.49M | 27.32M | 1.82M | -27.60M | -16.01M | 12.38M | -69.27M |
| Free Cash Flow | -39.09M | -38.86M | -7.44M | 9.60M | 8.05M | 4.05M | -6.23M | -5.04M | -5.86M | -16.86M | -32.23M | -41.34M |
This table shows 12 quarterly periods of GeneDx's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow WGS's reporting calendar. What is a cash flow statement?